Resistencia antimicrobiana

Saturn

Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria

The SATURN project aims to study the impact of antibiotic exposure on AMR with a multidisciplinary approach that bridges molecular, epidemiological, clinical and pharmacological research.

Two types of clinical studies will be conducted :

First, a randomised trial will be performed to resolve an issue of high controversy (antibiotic cycling vs. mixing).

Second, 3 observational studies will be conducted to rigorously study issues surrounding the effect of antibiotic use on AMR that are not easily assessable through randomised trials.

These clinical studies will serve as a platform to 2 complementary workpackages (microbiology & pharmacology) that will perform important investigations relevant to this call. The work package focusing on molecular studies will generate new evidence about the changes effected by antibiotic therapy on commensal organisms or opportunistic pathogens in the oropharyngeal, nasal and gastro-intestinal flora and study AMR mechanisms and the dissemination of successful clones of fluoroquinolone-resistant, carbapenem-resistant or extended-spectrum beta-lactamase harboring Gram-negative bacteria, MRSA and fluoroquinolone-resistant viridans streptococci.

The SATURN Consortium

SATURN is coordinated by Stephan Harbarth (University of Geneva) and brings together leading European researchers in antimicrobial resistance. The SATURN consortium is made of 13 partners from 11 countries including Switzerland, Italy, Israel, the Netherlands, Belgium, Poland, France, Spain, Germany, Serbia and Romania.